[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335189-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335189-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","addressing-the-knowledge-gap-in-the-genomic-landscape-and-tailored-therapeutic-approaches-to-adolescent-and-young-adult-cancers","Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers","","Adolescents and young adults (AYAs) form a small fraction of cancer patients, and their genomic characteristics and genome-matched treatment outcomes are insufficiently defined. A retrospective analysis compared Japanese AYA and older adult cohorts across genomic alterations, therapeutic evidence levels, and genome-matched therapy use by cancer type. AYAs showed distinct biomarker patterns and broadly similar matched-therapy utilization, with trends toward improved survival. Comprehensive genomic profiling-guided treatment provided promising progression-free survival results.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/addressing-the-knowledge-gap-in-the-genomic-landscape-and-tailored-therapeutic-approaches-to-adolescent-and-young-adult-cancers/335189/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/addressing-the-knowledge-gap-in-the-genomic-landscape-and-tailored-therapeutic-approaches-to-adolescent-and-young-adult-cancers/335189.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is the genomic landscape of adolescent and young adult (AYA) cancers important to study?","Question",{"text":63,"@type":64},"AYA patients represent a small proportion of cancer cases, so their genomic profiles and outcomes of genome-matched therapies are not well studied, making treatment challenging.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What differences were observed between AYA and older adult patients in genomic alterations?",{"text":68,"@type":64},"Microsatellite instability-high and/or tumor mutation burden were less common in AYA patients, while certain alterations were more frequent in AYA by cancer type (e.g., BRCA1 in breast cancer, MYC in colorectal cancer and sarcoma).",{"name":70,"@type":61,"acceptedAnswer":71},"How did comprehensive genomic profiling-guided genome-matched therapy affect outcomes?",{"text":72,"@type":64},"Genome-matched therapy use was similar overall, and outcomes showed encouraging trends; progression-free survival was longer in AYAs than in older adults, although statistical significance was limited by small AYA sample size.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335189,1790013064,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ORIGINAL RESEARCH  \nAddressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers  \nN. Hayashi1, 2, M. Ono3 , 4􀀁, I. Fukada1, M. Yamazaki1, 4, N. Sato1, M. Hosonaga5, X. Wang3, K. Kaneko2, H. Arakawa2,  \nE. Habano2, A. Kuga2, A. Kataoka5, A. Ueki2, K. Kiyotani6, 7, A. Tonooka8, 9, K. Takeuchi8 , 9, 10, T. Kogawa4, S. Kitano4,  \nT. Takano5, M. Watanabe11, S. Mori12 & S. Takahashi1, 3, 4  \n1Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 2Department of Clinical Genetic Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 3Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 4Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 5Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo; 6Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 7Laboratory of Immunogenomics, The Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka; 8Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 9Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 10Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 11Total Care Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 12Project for Development of Innovative Research on Cancer Therapeutics, The Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan  \nAvailable online xxx  \nBackground: Adolescents and young adults (AYAs) represent a small proportion of patients with cancer. The genomic proﬁles of AYA patients with cancer are not well-studied, and outcomes of genome-matched therapies remain largely unknown.  \nPatients and methods: We investigated differences between Japanese AYA and older adult (OA) patients in genomic alterations, therapeutic evidence levels, and genome-matched therapy usage by cancer type. We also assessed treatment outcomes.  \nResults: AYA patients accounted for 8 .3% of 876 cases. Microsatellite instability-high and/or tumor mutation burden was less common in AYA patients (1 .4% versus 7 .7% in OA; P ¼ 0.05) . However, BRCA1 alterations were more common in AYA patients with breast cancer (27 .3% versus 1 .7% in OA; P ¼ 0.01), as were MYC alterations in AYA patients with colorectal cancer (23 .5% versus 5 .8% in OA; P ¼ 0.02) and sarcoma (31 .3% versus 3 .4% in OA; P ¼ 0.01) . Genome-matched therapy use was similar between groups, with overall survival tending to improve in both. However, in AYA patients, the small number of patients prevented statistical signiﬁcance. Comprehensive genomic proﬁling-guided genome-matched therapy yielded encouraging results, with progression-free survival of 9.0 months in AYA versus 3 .7 months in OA patients (P ¼ 0.59) .  \nConclusion: Our study suggests that tailored therapeutic approaches can beneﬁt cancer patients regardless of age. Key words: adolescent, young adult, older adult, genomic proﬁling, genome-matched therapy, treatment outcome  \nINTRODUCTION  \nAdolescent and young adult (AYA) patients with cancer are generally deﬁned as those between the ages of 15 and 39 years at the time of their initial cancer diagnosis.1 According to the 2023 Surveillance Epidemiology and End Results database, the incidence of cancer among AYA patients has  \n*Correspondence to: Dr Makiko Ono, Department of Medical Oncology, The Cancer Institute Hospital of J","cbCaibxzRbLKg3Fj","https://ap.wps.com/l/cbCaibxzRbLKg3Fj","pdf",756328,"English","# Background\n# Patients and methods\n# Results\n## Genomic alterations and biomarker patterns\n## Genome-matched therapy usage and outcomes\n# Conclusion","[{\"question\":\"Why is the genomic landscape of adolescent and young adult (AYA) cancers important to study?\",\"answer\":\"AYA patients represent a small proportion of cancer cases, so their genomic profiles and outcomes of genome-matched therapies are not well studied, making treatment challenging.\"},{\"question\":\"What differences were observed between AYA and older adult patients in genomic alterations?\",\"answer\":\"Microsatellite instability-high and/or tumor mutation burden were less common in AYA patients, while certain alterations were more frequent in AYA by cancer type (e.g., BRCA1 in breast cancer, MYC in colorectal cancer and sarcoma).\"},{\"question\":\"How did comprehensive genomic profiling-guided genome-matched therapy affect outcomes?\",\"answer\":\"Genome-matched therapy use was similar overall, and outcomes showed encouraging trends; progression-free survival was longer in AYAs than in older adults, although statistical significance was limited by small AYA sample size.\"}]","Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers | PDF",1790010004,25]